| Drug General Information |
| Drug ID |
D0VF6E
|
| Former ID |
DNC001102
|
| Drug Name |
PD173074
|
| Synonyms |
FGFR inhibitors
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 2 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C28H41N7O3
|
| InChI |
InChI=1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)
|
| InChIKey |
DXCUKNQANPLTEJ-UHFFFAOYSA-N
|
| CAS Number |
CAS 114560-48-4
|
| PubChem Compound ID |
|
| PubChem Substance ID |
834654, 5359270, 7889759, 8035790, 8151133, 12015201, 14836471, 24439740, 24724575, 26758699, 29217621, 46394115, 49674688, 53790840, 57320895, 77522681, 99437062, 103102522, 103459751, 104297629, 117571944, 123220361, 124757129, 124800487, 124893193, 125163933, 125333800, 126731458, 131477697, 131480741, 134338999, 134340345, 134342600, 135352081, 135610525, 135686042, 135686043, 135686064, 135686065, 135698601, 136340183, 136367375, 136367834, 137183761, 139404141, 143496970, 144116352, 152234783, 152258172, 152344220
|
| Drug Resistance Mutation (DRM) |
| DRM |
DRM Info
|
| Target and Pathway |
| Target(s) |
Proto-oncogene tyrosine-protein kinase SRC |
Target Info |
Inhibitor |
[3]
|
|---|
| Fibroblast growth factor receptor |
Target Info |
Antagonist |
[4]
|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
Chemokine signaling pathway
|
|
Endocytosis
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Tight junction
|
|
Gap junction
|
|
Platelet activation
|
|
GABAergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson disease
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
Signaling events mediated by PRL
|
|
LPA receptor mediated events
|
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
Plasma membrane estrogen receptor signaling
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Signaling events mediated by PTP1B
|
|
S1P3 pathway
|
|
EPHB forward signaling
|
|
Nectin adhesion pathway
|
|
Regulation of p38-alpha and p38-beta
|
|
CDC42 signaling events
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
Netrin-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
CXCR4-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Class I PI3K signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Regulation of Androgen receptor activity
|
|
E-cadherin signaling in the nascent adherens junction
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
EPHA forward signaling
|
|
E-cadherin signaling in keratinocytes
|
|
PDGFR-beta signaling pathway
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-2-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
Syndecan-3-mediated signaling events
|
|
Ephrin B reverse signaling
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
EPHA2 forward signaling
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Alpha4 beta1 integrin signaling events
|
|
Signaling events mediated by focal adhesion kinase
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Pregnane X Receptor pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL-3 Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Angiogenesis
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5037). |
|---|
| REF 2 | ClinicalTrials.gov (NCT01441297) BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer. U.S. National Institutes of Health. |
|---|
| REF 3 | Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. |
|---|
| REF 4 | Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. |
|---|
